PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...

Columnist Desiree Lama has accepted her MS diagnosis as part of her identity — but it's not the only thing that defines her, ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

Gaps in access to care persist for US patients with MS and impact HRQOL to a large extent. Improving access to care for patients with MS should be prioritized.

Ms Corner said it shows "the part of John’s story that is rarely seen beyond his closest family" as he lies pensive in bed.

Stay informed and make judicious decisions using our Ratings Table. Biogen and Idec merged in 2003, combining forces to ...

OAB has many possible causes, including diseases like diabetes and multiple sclerosis (MS) that cause bladder nerve ...

Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

Maureen Sharphouse made countless visits to countless doctors before she found out she suffered from Ehlers Danlos syndrome.

Longevity is becoming increasingly popular to elongate health-span. We turn to estrogen to understand its impact on women's ...

After years of caring for others, Auckland nurse Zazi Gohar faced her own health crisis when she was diagnosed with multiple ...

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease.